Welcome to our dedicated page for Aeon Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode AEON Biopharma’s merger accounting notes or ABP-450 trial updates buried inside its latest 10-K? Our platform turns hundreds of biotech-specific pages into clear insights in minutes. Stock Titan’s AI-powered summaries spotlight cash runway disclosures, FDA milestone risks, and AEON Biopharma annual report 10-K simplified so you can focus on what moves the share price.
Every regulatory document—whether a fast-moving AEON Biopharma 8-K material events explained, a detailed AEON Biopharma quarterly earnings report 10-Q filing, or AEON Biopharma insider trading Form 4 transactions—appears here the moment it hits EDGAR. Our AI tags sections discussing ABP-450 efficacy data, merger-related goodwill, or PIPE financing, then delivers plain-English takeaways. Need the raw numbers? Download full text and exhibits or skim our red-line comparisons between quarters.
Common investor tasks become simple:
- Track AEON Biopharma Form 4 insider transactions real-time and spot patterns before trial readouts.
- Compare R&D spend across periods with one click using our AEON Biopharma earnings report filing analysis.
- Review AEON Biopharma proxy statement executive compensation without scrolling through boilerplate.
Whether you are understanding AEON Biopharma SEC documents with AI for the first time or monitoring daily updates, our coverage of 10-K, 10-Q, Form 4, S-4, and more delivers the detail serious biotech investors need—minus the complexity.
AEON Biopharma reported a period of transition as it pivots ABP-450 development toward a biosimilar pathway after discontinuing Phase 2 migraine trials in May 2024. The company completed a 1-for-72 reverse stock split and raised net proceeds of approximately $18.3 million from a January 2025 public offering and has an ATM program with about $49.8 million remaining. As of June 30, 2025, AEON held $8.4 million in cash and total assets of $11.7 million, against total liabilities of $27.5 million, resulting in a stockholders' deficit of $15.9 million. The company recorded a $75.6 million non‑cash loss on warrant issuance and recognized fair value movements on convertible notes and contingent consideration that materially affected reported (loss) income. Management discloses substantial doubt about the company’s ability to continue as a going concern and states additional financing will be required to advance analytical studies, a planned FDA BPD Type 2a meeting and further development of ABP-450.
FAQ
What is the current stock price of Aeon Biopharma (AEON)?
What is the market cap of Aeon Biopharma (AEON)?
